Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
KENEXA CORP (KNXA)
|
Add to portfolio |
|
|
|
| Price: |
$23.75
| | Metrics |
| OS: |
27.6
|
M
| |
-3
|
% ROE
|
| Market cap: |
$656
|
M
| |
-12
|
% ROIC
|
|
Net cash:
|
$59.8
|
M
| |
$2.17
|
per share
|
|
EV:
|
$596
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$38.7
|
M
| |
15.4
|
x EV/EBITDA
|
|
EBIT
|
($2.3)
|
M
| |
|
|
| EPS |
($0.28)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 |
| Revenues | 282.9 | 196.4 | 157.7 | 203.7 | 181.9 | 112.1 | 65.6 | 46.3 |
| Revenue growth | 44.1% | 24.5% | -22.6% | 12.0% | 62.3% | 70.8% | 41.8% | 36.2% |
| Cost of goods sold | 112.2 | 68.4 | 53.4 | 61.6 | 50.9 | 31.7 | 18.8 | 12.2 |
| Gross profit | 170.8 | 127.9 | 104.3 | 142.1 | 131.0 | 80.4 | 46.9 | 34.1 |
| Gross margin | 60.4% | 65.1% | 66.1% | 69.8% | 72.0% | 71.7% | 71.4% | 73.6% |
| Sales and marketing | 63.4 | 48.2 | 35.2 | 40.8 | 35.3 | 25.1 | 16.1 | 13.4 |
| Research and development | 19.1 | 11.9 | 9.8 | 15.6 | 17.7 | 8.6 | 4.0 | 4.3 |
| General and administrative | 53.9 | 48.5 | 40.8 | 48.9 | 39.3 | 24.5 | 15.1 | 10.2 |
| EBIT | 1.9 | -0.3 | 4.3 | 24.8 | 31.0 | 18.6 | 9.5 | 3.7 |
| EBIT margin | 0.7% | -0.2% | 2.7% | 12.2% | 17.1% | 16.6% | 14.5% | 8.1% |
| Pre-tax income | 0.1 | -0.7 | -29.1 | -142.8 | 34.1 | 20.2 | 6.7 | -4.8 |
| Income taxes | 4.0 | 2.3 | 1.9 | -38.1 | 10.6 | 4.3 | 0.6 | -0.7 |
| Tax rate | 4708.3% | | | 26.7% | 31.0% | 21.3% | 8.8% | 15.0% |
| Net income | -4.1 | -3.6 | -31.1 | -104.7 | 23.5 | 15.9 | 0.0 | 0.0 |
| Net margin | -1.5% | -1.8% | -19.7% | -51.4% | 12.9% | 14.2% | -0.1% | 0.0% |
| |
| Diluted EPS | ($0.16) | ($0.16) | ($1.38) | ($4.60) | $0.93 | $0.78 | ($3.06) | ($0.85) |
| Shares outstanding (diluted) | 25.5 | 22.6 | 22.5 | 22.8 | 25.3 | 20.4 | 0.0 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|